Technavio has announced its latest pipeline analysis report on the sinusitis
market. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat chondrosarcoma.
This press release features multimedia. View the full release here:
Technavio has published a new report on the drug development pipeline for sinusitis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the coming years.
This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing
Sinusitis: Market analysis
The hollow space, a channel containing blood or a cavity within the bone
in the human body is known as a sinus. There are different types of
sinuses but, the sinus infection that impacts the spaces behind the head
connecting to the nasal cavity is termed as sinusitis. Sinusitis occurs
when the mucus starts building up in the nose, inflating the sinuses.
Various factors can result in sinusitis, but the major factor that leads
to sinusitis is the fluid that gets trapped into the sinus.
According to a senior analyst at Technavio for research on infectious
and rare diseases, “There are two different types of sinusitis,
including acute sinusitis and chronic sinusitis. Acute sinusitis is the
most common type of sinusitis, which makes the cavities around the nasal
passage inflamed and swollen. Chronic sinusitis is persistent sinusitis
that lasts for more than 12 weeks along with the medical care.”
Sinusitis: Segmentation analysis
This market research report segments the sinusitis market based on
therapies employed (monotherapy and unknown), RoA (inhalation,
intranasal, oral, subcutaneous, and unknown), therapeutic modalities
(monoclonal antibody, biological, small molecule, recombinant protein,
and unknown), targets (DNA and RNA, glucocorticoid, IgE receptor, IL-5
receptor, protein, and unknown), MoA (bacterial DNA and RNA modulator,
glucocorticoid receptor agonist, IgE receptor inhibitor, IL-5 receptor
inhibitor, protein synthesis inhibitor, and protein replacement), and
recruitment status (recruiting, active not recruiting, completed, and
Monotherapy includes the use of a single drug to treat a disorder or a
disease. In the current pipeline, around 5 molecules that are being
investigated for the treatment of sinusitis belong to this category.
Inhalation RoA involves the inhaling of medicines or anesthetics in the
form of a gas or a vapor. In the current pipeline, one molecule is
administered through the inhalation mode.
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
Drug Development Strategies
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005675/en/